+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07782957

Randomized Study of GSK5784283 Felcorekibart Versus Placebo as Add-On Maintenance Therapy in Adults With Chronic Rhinosinusitis With Nasal Polyps

Led by GlaxoSmithKline · Updated on 2026-10-09

218

Participants Needed

4

Research Sites

34 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of GSK5784283 Felcorekibart as an add-on maintenance treatment for adults with chronic rhinosinusitis with nasal polyps CRSwNP. This Phase 3 randomized, double-blind study compares GSK5784283 plus standard of care against placebo plus standard of care to better understand its effects on nasal polyps and related symptoms. Participants will be randomly assigned to receive either GSK5784283 or a placebo alongside their standard treatment. The study lasts for 52 weeks, during which the main focus is on changes in nasal polyp size and nasal obstruction symptoms. Additional assessments include loss of smell, composite symptom scores, CT scan scores, quality of life questionnaires, and time to surgery or additional medication use. Throughout the study, participants will undergo evaluations including endoscopic examinations, symptom scoring, CT scans, and questionnaires at baseline and Week 52. Researchers will monitor asthma control and track the use of corticosteroids or surgical decisions related to nasal polyps. The total participation time spans about one year with safety and symptom monitoring conducted regularly.

CONDITIONS

Brief Title

A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Research Team

U

US GSK Clinical Trials Call Center

E

EU GSK Clinical Trials Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here